Elias Eriksson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4372385/publications.pdf Version: 2024-02-01



FLINS FRIKSSON

#	Article	IF	CITATIONS
1	Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo. Translational Psychiatry, 2022, 12, 160.	4.8	0
2	Testosterone associates differently with body mass index and age in serum and cerebrospinal fluid in men. Journal of Internal Medicine, 2022, 292, 684-686.	6.0	3
3	Genome-wide association study of panic disorder reveals genetic overlap with neuroticism and depression. Molecular Psychiatry, 2021, 26, 4179-4190.	7.9	58
4	Low SSRI dosing in clinical practice—a registerâ€based longitudinal study. Acta Psychiatrica Scandinavica, 2021, 143, 434-443.	4.5	6
5	Serotonin depletion reduces both acquisition and expression of context-conditioned fear. Acta Neuropsychiatrica, 2021, 33, 148-155.	2.1	2
6	Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis. Translational Psychiatry, 2021, 11, 249.	4.8	11
7	Determining maximal achievable effect sizes of antidepressant therapies in placeboâ€controlled trials. Acta Psychiatrica Scandinavica, 2021, 144, 300-309.	4.5	2
8	A Complex Impact of Systemically Administered 5-HT2A Receptor Ligands on Conditioned Fear. International Journal of Neuropsychopharmacology, 2021, 24, 749-757.	2.1	10
9	Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study. Neuropsychopharmacology, 2020, 45, 553-560.	5.4	22
10	Good news regarding SSRI safety in Danish meta-analysis. Acta Neuropsychiatrica, 2020, 32, 54-56.	2.1	0
11	Neuroimaging, genetic, clinical, and demographic predictors of treatment response in patients with social anxiety disorder. Journal of Affective Disorders, 2020, 261, 230-237.	4.1	24
12	Torgny Svensson, a superb mind and an inspiring colleague. International Journal of Neuropsychopharmacology, 2020, 23, 543-544.	2.1	0
13	Torgny Svensson, M.D., Ph.D. (1945–2020). Neuropsychopharmacology, 2020, 45, 1960-1960.	5.4	0
14	Individual variability in treatment response to antidepressants in major depression: comparing trialâ€level and patientâ€level analyses. Acta Psychiatrica Scandinavica, 2020, 142, 443-445.	4.5	5
15	Expression of 22 serotonin-related genes in rat brain after sub-acute serotonin depletion or reuptake inhibition. Acta Neuropsychiatrica, 2020, 32, 159-165.	2.1	1
16	Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. Lancet Psychiatry,the, 2019, 6, 745-752.	7.4	50
17	5-HT6 receptor antagonism reduces defecation in rat: A potential treatment strategy for irritable bowel syndrome with diarrhea. European Journal of Pharmacology, 2019, 864, 172718.	3.5	3
18	How do we determine whether antidepressants are useful or not? – Authors' reply. Lancet Psychiatry,the, 2019, 6, 888-889.	7.4	0

#	Article	IF	CITATIONS
19	Selective serotonin reuptake inhibition increases noise burst-induced unconditioned and context-conditioned freezing. Acta Neuropsychiatrica, 2019, 31, 46-51.	2.1	4
20	Effects of selective serotonin reuptake inhibitors on rating-scale-assessed suicidality in adults with depression. British Journal of Psychiatry, 2018, 212, 148-154.	2.8	23
21	Multiple possible inaccuracies cast doubt on a recent report suggesting selective serotonin reuptake inhibitors to be toxic and ineffective. Acta Neuropsychiatrica, 2018, 30, 244-250.	2.1	9
22	Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. Molecular Psychiatry, 2018, 23, 1731-1736.	7.9	31
23	Katakam and co-workers have not shown SSRIs to be harmful and ineffective and should stop claiming that they have. Acta Neuropsychiatrica, 2018, 30, 266-274.	2.1	1
24	The alleged lack of efficacy of antidepressants in nonâ€severe depression: a myth debunked. Acta Psychiatrica Scandinavica, 2018, 137, 447-449.	4.5	6
25	Effect of 5-HT6 receptor antagonists on stress-induced defecation in rat: possible relevance for the treatment of irritable bowel syndrome. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-5-17.	0.0	Ο
26	A genetic association study of CSMD1 and CSMD2 with cognitive function. Brain, Behavior, and Immunity, 2017, 61, 209-216.	4.1	49
27	Specific patterns of whole-brain structural covariance of the anterior and posterior hippocampus in young APOE ε4 carriers. Behavioural Brain Research, 2017, 326, 256-264.	2.2	12
28	Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression. Acta Psychiatrica Scandinavica, 2017, 136, 343-351.	4.5	16
29	The ACE Gene Is Associated with Late-Life Major Depression and Age at Dementia Onset in a Population-Based Cohort. American Journal of Geriatric Psychiatry, 2017, 25, 170-177.	1.2	13
30	Disentangling the effects of serotonin on risk perception: S-carriers of 5-HTTLPR are primarily concerned with the magnitude of the outcomes, not the uncertainty Behavioral Neuroscience, 2017, 131, 421-427.	1.2	2
31	PS02. Both chronic SSRI administration and serotonin depletion impairs context conditioned freezing behaviour. International Journal of Neuropsychopharmacology, 2016, 19, 1-1.	2.1	0
32	Effects of gonadectomy and serotonin depletion on inter-individual differences in anxiety-like behaviour in male Wistar rats. Behavioural Brain Research, 2016, 308, 160-165.	2.2	8
33	Serotonin depletion eliminates sex differences with respect to context-conditioned immobility in rat. Psychopharmacology, 2016, 233, 1513-1521.	3.1	13
34	Inclusion of Flexible-Dose Trials in the Meta-Analysis of SSRI Dose-Dependency. American Journal of Psychiatry, 2016, 173, 836-836.	7.2	3
35	The effects of the dopamine stabilizer (â^)-OSU6162 on aggressive and sexual behavior in rodents. Translational Psychiatry, 2016, 6, e762-e762.	4.8	5
36	Serotonin synthesis rate and the tryptophan hydroxylase-2: G-703T polymorphism in social anxiety disorder. Journal of Psychopharmacology, 2016, 30, 1028-1035.	4.0	33

#	Article	IF	CITATIONS
37	Effect of co-twin gender on neurodevelopmental symptoms: a twin register study. Molecular Autism, 2016, 7, 8.	4.9	17
38	A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Translational Psychiatry, 2016, 6, e834-e834.	4.8	75
39	Apolipoprotein E ϵ4 is positively related to spatial performance but unrelated to hippocampal volume in healthy young adults. Behavioural Brain Research, 2016, 299, 11-18.	2.2	14
40	Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Molecular Psychiatry, 2016, 21, 523-530.	7.9	144
41	Polymorphisms of dopamine pathway genes <i><scp>NRG</scp>1</i> and <i><scp>LMX</scp>1A</i> are associated with cognitive performance in bipolar disorder. Bipolar Disorders, 2015, 17, 859-868.	1.9	23
42	Differences in Anxiety-Like Behavior within a Batch of Wistar Rats Are Associated with Differences in Serotonergic Transmission, Enhanced by Acute SRI Administration, and Abolished By Serotonin Depletion. International Journal of Neuropsychopharmacology, 2015, 18, .	2.1	28
43	Acute escitalopram but not contextual conditioning exerts a stronger "anxiogenic―effect in rats with high baseline "anxiety―in the acoustic startle paradigm. Psychopharmacology, 2015, 232, 1461-1469.	3.1	8
44	Serotonin Depletion-Induced Maladaptive Aggression Requires the Presence of Androgens. PLoS ONE, 2015, 10, e0126462.	2.5	13
45	SSRIs probably counteract premenstrual syndrome by inhibiting the serotonin transporter. Journal of Psychopharmacology, 2014, 28, 173-174.	4.0	4
46	Association between amygdala reactivity and a dopamine transporter gene polymorphism. Translational Psychiatry, 2014, 4, e420-e420.	4.8	23
47	Comment on "An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice― Science Translational Medicine, 2014, 6, 268le5.	12.4	8
48	Application of the Gradient Boosted method in randomised clinical trials: Participant variables that contribute to depression treatment efficacy of duloxetine, SSRIs or placebo. Journal of Affective Disorders, 2014, 168, 284-293.	4.1	16
49	Serotonin depletion counteracts sex differences in anxiety-related behaviour in rat. Psychopharmacology, 2013, 230, 29-35.	3.1	21
50	Estrogen receptor α (ERα) expression in neuronal cells affects bone mass. Annals of the Rheumatic Diseases, 2012, 71, A65.1-A65.	0.9	0
51	Short Onset of Action of a Serotonin Reuptake Inhibitor When Used to Reduce Premenstrual Irritability. Neuropsychopharmacology, 2009, 34, 585-592.	5.4	36
52	Genotype over-diagnosis in amygdala responsiveness: affective processing in social anxiety disorder. Journal of Psychiatry and Neuroscience, 2009, 34, 30-40.	2.4	56
53	Escitalopram Administered in the Luteal Phase Exerts a Marked and Dose-Dependent Effect in Premenstrual Dysphoric Disorder. Journal of Clinical Psychopharmacology, 2008, 28, 195-202.	1.4	45
54	Phenotypic and genotypic characteristics of women in relation to personality traits. International Journal of Behavioral Medicine, 2003, 10, 364-378.	1.7	17

#	Article	IF	CITATIONS
55	A Polymorphism in the Serotonin Receptor 3A (HTR3A) Gene and Its Association With Harm Avoidance in Women. Archives of General Psychiatry, 2003, 60, 1017.	12.3	81
56	New perspectives on the treatment of premenstrual syndrome and premenstrual dysphoric disorder. Archives of Women's Mental Health, 2002, 4, 111-119.	2.6	10
57	Diagnosis and treatment of premenstrual dysphoria. Journal of Clinical Psychiatry, 2002, 63 Suppl 7, 16-23.	2.2	13
58	Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology, 2001, 155, 292-298.	3.1	54
59	Serotonin transporter gene polymorphisms are associated with anxietyâ€related personality traits in women. American Journal of Medical Genetics Part A, 2001, 105, 458-463.	2.4	122
60	Antidepressant drugs: does it matter if they inhibit the reuptake of noradrenaline or serotonin?. Acta Psychiatrica Scandinavica, 2000, 101, 12-17.	4.5	31
61	Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. International Clinical Psychopharmacology, 1999, 14 Suppl 2, S27-33.	1.7	14
62	Direct dopamine D2 -receptor-mediated modulation of arachidonic acid release in transfected CHO cells without the concomitant administration of a Ca2+ -mobilizing agent. British Journal of Pharmacology, 1998, 124, 1651-1658.	5.4	30
63	Central administration of dopamine D3 receptor antisense to rat: effects on locomotion, dopamine release and [3H]spiperone binding. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 358, 342-350.	3.0	37
64	The pharmacological treatment of premenstrual dysphoria. European Psychiatry, 1998, 13, 179s-179s.	0.2	0
65	Subchronic Administration of Fluoxetine Impairs Estrous Behavior in Intact Female Rats. Neuropsychopharmacology, 1998, 19, 492-498.	5.4	53
66	Reduced extracellular levels of serotonin in the amygdala of androgenized female rats. European Neuropsychopharmacology, 1997, 7, 253-259.	0.7	36
67	Effects of Remoxipride and Raclopride on Prolactin Release from Clonal Pituitary Tumour Cells. Basic and Clinical Pharmacology and Toxicology, 1995, 76, 85-88.	0.0	1
68	Sodium Lactate Elicits a Rapid Increase in Blood Pressure in Wistar Rats and Spontaneously Hypertensive Rats Effect of Pretreatment with the Antipanic Drugs Clomipramine and Alprazolam. Neuropsychopharmacology, 1995, 12, 245-250.	5.4	10
69	Cerebrospinal Fluid Levels of Monoamine Metabolites. Neuropsychopharmacology, 1994, 11, 201-213.	5.4	48
70	Clomipramine Administered during the Luteal Phase Reduces the Symptoms of Premenstrual Syndrome: A Placebo-Controlled Trial. Neuropsychopharmacology, 1993, 9, 133-145.	5.4	166
71	Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinology, 1992, 17, 195-204.	2.7	116
72	Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. Journal of Clinical Psychopharmacology, 1992, 12, 251-61.	1.4	32

#	Article	IF	CITATIONS
73	Penetration forces in cannulation of the dorsal veins of the hand: I. A comparison between polyurethane (Insyte®) and polytetrafluoroethylene (Venflon®) cannulae. Acta Anaesthesiologica Scandinavica, 1991, 35, 306-314.	1.6	9
74	Effect of clomipramine on premenstrual syndrome. Acta Psychiatrica Scandinavica, 1990, 81, 87-88.	4.5	53
75	Neuropeptides in human CSF. Acta Neurologica Scandinavica, 1989, 79, 261-262.	2.1	0
76	Increased cerebrospinal fluid levels of endorphin immunoreactivity in panic disorder. Neuropsychopharmacology, 1989, 2, 225-228.	5.4	16
77	The effect of various anticoagulant/antiplatelet mixtures on determination of plasminogen activator inhibitor, platelet proteins and hemostasis parameters. Thrombosis and Haemostasis, 1989, 61, 511-6.	3.4	4
78	Effects of sex steroids on growth hormone responses to clonidine and GHRH in reserpine pretreated rats. Journal of Neural Transmission, 1988, 71, 99-113.	2.8	14
79	Growth hormone responses to the alpha2-adrenoceptor agonist guanfacine and to growth hormone releasing hormone in depressed patients and controls. Psychiatry Research, 1988, 26, 59-67.	3.3	23
80	Growth hormone response to clonidine as a biological marker in psychiatric research – A review of the literature. Nordic Journal of Psychiatry, 1988, 42, 123-129.	0.1	0
81	Brain neurotransmission in panic disorder. Acta Psychiatrica Scandinavica, 1987, 76, 31-37.	4.5	23
82	A Central Serotonin Receptor Agonist, 8â€Hydroxyâ€2â€(diâ€nâ€propylamino)tetralin, has Different Effects on Prolactin Secretion in Male and Female Rats. Acta Pharmacologica Et Toxicologica, 1986, 58, 297-302.	0.0	22
83	Rat brain serotonin: Biochemical and functional evidence for a sex difference. Journal of Neural Transmission, 1985, 63, 297-313.	2.8	115
84	Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease. Neurology, 0, , 10.1212/WNL.0000000000200804.	1.1	9